<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182179</url>
  </required_header>
  <id_info>
    <org_study_id>ORL-CHIR-001</org_study_id>
    <nct_id>NCT03182179</nct_id>
  </id_info>
  <brief_title>Efficacy of Ondansetron in LARS Treatment</brief_title>
  <acronym>Hodolar</acronym>
  <official_title>Efficacy of Ondansetron in the Treatment of Low Anterior Resection Syndrome (LARS): a Multi-centre, Randomized, Double Blind, Placebo-controlled Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ente Ospedaliero Cantonale, Bellinzona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ente Ospedaliero Cantonale, Bellinzona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will be randomized (1:1 ratio) to receive either 4 weeks of Ondansetron followed by&#xD;
      4 weeks of placebo (O-P sequence) or 4 weeks of placebo followed by 4 weeks of Ondansetron&#xD;
      (P-O sequence). It will be one week of washout between the two treatments.&#xD;
&#xD;
      During the treatment questionnaires will be completed by the patients to evaluate the&#xD;
      efficacy of the study treatment and the quality of live.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre randomized, double-blind, placebo-controlled, cross-over study aimed&#xD;
      at testing the efficacy of Ondansetron in the low anterior resection syndrome (LARS)&#xD;
      occurring as a consequence of surgery for rectal cancer.&#xD;
&#xD;
      Patients will be randomized (1:1 ratio) to receive either 4 weeks of Ondansetron followed by&#xD;
      4 weeks of placebo (O-P sequence) or 4 weeks of placebo followed by 4 weeks of Ondansetron&#xD;
      (P-O sequence). Neither the investigator nor the patient will be aware of the sequence (O-P&#xD;
      or P-O) assigned to the patient. One week will elapse between the end of the first treatment&#xD;
      and start of the second treatment.&#xD;
&#xD;
      The hypothesis to be tested is that 4 weeks of oral Ondansetron at the dose of 4mg BID induce&#xD;
      a variation of the LARS Score at least 7 points (20%) greater than the variation occurring&#xD;
      after 4 weeks of placebo.&#xD;
&#xD;
      The sample size calculated for the primary analysis is 38 evaluable patients. Considering an&#xD;
      expected attrition rate of about 20%, it is expected to enrol approximately 46 patients in&#xD;
      total.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LARS score</measure>
    <time_frame>10 wks</time_frame>
    <description>The primary outcome is the change in LARS Score assessed before and after Ondansetron and placebo treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaizey (St. Mark's) score</measure>
    <time_frame>10 wks</time_frame>
    <description>Change in Vaizey (St. Mark's) Score assessed before and at the end of Ondansetron and placebo treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Irritable Bowel Syndrome-Quality of Life</measure>
    <time_frame>10 wks</time_frame>
    <description>Irritable Bowel Syndrome-Quality of Life (IBS-QoL) assessed before and at the end of Ondansetron and placebo treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>O-P sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive of oral Ondansetron 4mg BD for 28 days followed by 28 days of placebo. It will be one week of washout between the two treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>P-O sequence</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive oral placebo for 28 days followed by Ondansetron 4mg BD for 28 days. It will be one week of washout between the two treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 4 MG</intervention_name>
    <description>Ondansetron is taken orally BD</description>
    <arm_group_label>O-P sequence</arm_group_label>
    <arm_group_label>P-O sequence</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is taken orally BD</description>
    <arm_group_label>O-P sequence</arm_group_label>
    <arm_group_label>P-O sequence</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Patients willing and able to comply with the study procedures&#xD;
&#xD;
          -  Female patients of childbearing potential must agree to use a reliable method of&#xD;
             contraception&#xD;
&#xD;
          -  Written informed consent Patients who have undergone low anterior resection (LAR) for&#xD;
             rectal cancer in the last 2 years provided that at least 4 weeks have elapsed since&#xD;
             recanalization and 4 weeks have elapsed since any chemo- and/or radiotherapy&#xD;
&#xD;
          -  Presence of functioning anastomosis&#xD;
&#xD;
          -  Presence of significant LARS symptoms assessed by LARS Score&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to Ondansetron&#xD;
&#xD;
          -  Previous Ondansetron antiemetic therapy completed less than 4 weeks before study entry&#xD;
&#xD;
          -  Antitumor chemotherapy or radiotherapy completed less than 4 weeks before study entry&#xD;
&#xD;
          -  Congenital long Q-T syndrome&#xD;
&#xD;
          -  Ongoing treatment with drugs causing prolongation of the Q-T interval&#xD;
&#xD;
          -  Uncorrected hypokalemia or hypomagnesemia&#xD;
&#xD;
          -  Women who are pregnant or breast feeding or are willing to become pregnant during the&#xD;
             study&#xD;
&#xD;
          -  Clinically significant concomitant disease states or anastomotic complications which&#xD;
             could impair the ability of the patient to participate in the trial&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitri Christoforidis, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale Regionale di Lugano, Civico e Italiano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dimitri Christoforidis, Prof.</last_name>
    <phone>+41 (0)91 811 69 56</phone>
    <email>dimitri.christoforidis@eoc.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seraina Faes, MD</last_name>
      <phone>+41 (0)79 55 67502</phone>
      <email>seraina.faes@chuv.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Regionale di Lugano, Civico e Italiano</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Christoforidis, Prof.</last_name>
      <phone>+41 (0)91 811 69 56</phone>
      <email>dimitri.christoforidis@eoc.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

